Fiche publication
Date publication
janvier 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GANGLOFF Sophie
,
Pr GRAESSLIN Olivier
,
Dr VELARD Frédéric
,
Dr KERDJOUDJ Halima
Tous les auteurs :
Mechiche Alami S, Velard F, Draux F, Siu Paredes F, Josse J, Lemaire F, Gangloff SC, Graesslin O, Laurent-Maquin D, Kerdjoudj H
Lien Pubmed
Résumé
Stem cells are the most powerful candidate for the treatment of various diseases. Suitable stem cell source should be harvested with minimal invasive procedure, found in great quantity, and transplanted with no risk of immune response and tumor formation. Fetal derived stem cells have been introduced as an excellent alternative to adult and embryonic stem cells use, but unfortunately, their degree of "stemness" and molecular characterization is still unclear. Several studies have been performed deciphering whether fetal stem cells meet the needs of regenerative medicine. We believe that a transcriptomic screening of Wharton's jelly stem cells will bring insights on cell population features.
Référence
Biomed Mater Eng. 2014;24(1 Suppl):53-61
